Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TeMP: Inhalation vs TIVA in Breast Cancer Surgery
NCT04800393Recruiting
- Sponsor
- Loginov Moscow Clinical Scientific Center
- Start
- Mar 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of sevoflurane in breast cancer (2 arms), sponsored by Loginov Moscow Clinical Scientific Center. Primary endpoint: Neutrophil-lymphocyte ratio. Started Mar 2022; status: recruiting.
02
Drugs
sevoflurane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04800393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04800393.